Eisai aims to improve business efficiency and productivity and promptly maximize contribution to patients by leveraging global partnerships.
-
*Details of the agreements below are as of the end of March 2021.
Strategic Collaboration
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
|
Biogen (U.S.A.)
|
March 4, 2014
|
1. Acquisition of option rights for co-development/co-promotion of the Eisaideveloped
anti-amyloid beta(Aβ) protofibril antibody BAN2401 (generic name: lecanemab) and the BACE
inhibitor E2609 (generic name: elenbecestat)*, and co-development/ co-promotion of a Biogendeveloped
anti-tau antibody
2. Co-development/ co-promotion of the Biogendeveloped anti-Aβ antibody
BIIB037 (generic name: aducanumab)
|
| U.S. Merck |
March 7, 2018
|
Co-development/co-promotion of Eisai’s anticancer agent Lenvima as monotherapy and in
combination with U.S. Merck’s anti-PD-1 antibody Keytruda for a number of cancer types
|
| Nichi-Iko Pharmaceutical Co., Ltd. |
March 28, 2018
|
1. Collaboration in building the Company’s Total Inclusive Ecosystem
2. Partnership in the active pharmaceutical ingredient business
|
* In September 2019, Biogen and Eisai discontinued Phase III testing to verify the efficacy and safety of E2609 (generic name:
elenbecestat).
Licensing
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
|
Fujifilm Corporation
Toyama Chemical Co., Ltd.
|
September 30, 1998
|
Joint development of and marketing alliance for the rheumatoid arthritis agent Careram (generic name: iguratimod)
|
|
AbbVie Deutschland GmbH & Co. KG (Germany)
|
June 16, 1999 |
Development and sale of the anti-TNF-α monoclonal antibody Humira (generic name: adalimumab) in Japan and South Korea
|
|
Novartis AG (Switzerland)
|
February 6, 2004 |
License for worldwide development, manufacturing, and sale of the antiepileptic agent Inovelon (generic name: rufinamide)
|
|
Sunovion Pharmaceuticals Inc. (U.S.A.)
|
July 26, 2007 |
Exclusive license for the development and marketing of the insomnia treatment Lunesta (generic name: eszopiclone) in Japan
|
|
BioArctic (Sweden)
|
December 3, 2007 |
Exclusive license for worldwide research and development,manufacturing, and sale of the anti-Aβ protofibrils antibody BAN2401 (generic name: lecanemab) for the treatment of Alzheimer’s disease
|
|
Pfizer Inc. (U.S.A.)
|
September 24, 2009 | Co-promotion agreement in Japan for the pain treatment agent Lyrica (generic name: pregabalin) |
| Prism BioLab Co., Ltd. |
April 1, 2011
|
Exclusive license for worldwide development, manufacturing, and sale of the anticancer agent E7386 |
|
University of London (U.K.)
|
October 16, 2015 | Collaborative research and co-development of the anti-tau antibody E2814 |
|
Meiji Seika Pharma Co., Ltd.
|
March 31, 2017 | Licenses related to exclusive sales rights in Japan and exclusive development and sales rights in 7 Asian countries for the anti-Parkinson’s disease agent Equfina (generic name: safinamide) |
|
Harvard University (U.S.A.)
|
June 15, 2018 |
Exclusive license for worldwide development, manufacturing, and sale of anticancer agent E7130
|
|
Gilead Sciences, Inc.
|
December 24, 2019
|
Marketing alliance contract for the selective Janus kinase 1 inhibitor filgotinib (generic name) in Japan |
| Minophagen Pharmaceutical Co., Ltd. |
February 29, 2016
|
1. Exclusive development and sales rights of the liver disease/allergic disease agents Stronger Neo- Minophagen C (glycyrrhizic acid, compound formulation) and Glycyron Tablets (glycyrrhizic acid, compound tablet) in China and other parts of Asia
2. Exclusive sales rights of the liver disease/allergic disease agents Stronger Neo- Minophagen C (glycyrrhizic acid, compound formulation)
and Glycyron Tablets (glycyrrhizic acid, compound tablet) in Japan
|
* In July 2020, the exclusive development and marketing rights license agreement for the Company’s Stronger Neo-Minophagen
C and Glycyron Tablets were extended until March 31, 2033.
* In February 2021, Eisai Europe Ltd. (U.K.) ended the marketing license agreement and co-promotion agreement of the
antiepileptic agent Zebinix (generic name: eslicarbazepine) in Europe it had concluded with BIAL - Portela & Ca., S.A.
(Portugal).
In August 2019, the contract for development and sale of Humira in Taiwan ended.
Joint Venture
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
| Ajinomoto Co., Inc. | October 15, 2015 | Integration agreement concerning the splitting off of a portion of Eisai’s business and its subsequent succession by Ajinomoto Pharmaceuticals Co., Ltd. via an absorption-type split, etc. |
Other Contracts Important for Business
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
|
World Health Organization (WHO) (Switzerland)
|
January 30, 2012 | Provision of DEC (generic name: diethylcarbamazine) tablets to the WHO free of charge to support its program to eliminate lymphatic filariasis |